Photocure ASA - Repurchase program of own shares

Share this article
Published: 5 December 2011Financial Investment & Stock

PHOTOCURE - REPURCHASE PROGRAM OF OWN SHARES

Oslo, Norway, 5 December 2011:

According to the resolution made by the Annual General Meeting on 27 April 2011, the Board of Directors of Photocure ASA was given Power of Attorney to acquire own shares in connection with employee share purchase program. In accordance with the resolution, the Board of Directors of Photocure ASA has decided to acquire up to 250 000 shares.

The repurchase program will be initiated today, and will be carried out in accordance with the resolution from the Annual General Meeting. For more details on the program, please download the minutes from www.photocure.com (under Investors/Share information).

For further information contact:

Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no

M:Communications
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email: photocure@mcomgroup.com

About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic technology. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology(TM). Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure's bladder cancer diagnostic product, Hexvix is approved in Europe and the US. In addition, the company markets Allumera®, a photodynamic cosmetic in the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology(TM) is continuously being tested for new products and applications in cancer and dermatology. Allumera®, Photocure® and Hexvix® are registered trademarks of Photocure ASA. For more information about Photocure, visit www.photocure.com.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)
Share this article

News and events